BionimeTPE:4737 +0.89%65 Dividend Payout Ratio is 0.00 as of Dec. 2025. GuruFocus rates TPE:4737 with a GF Score™ of 65/100 and a GF Value™ of NT$58.88 (Fairly Valued). The stock has 7 warning signs investors should review. Among 281 Medical Devices & Instruments companies, Bionime ranks worse than 355871.53% on this metric.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Bionime's Dividend Payout Ratio for the
months ended in Dec. 2025 was 0.00.
The historical rank and industry rank for Bionime's Dividend Payout Ratio or its related term are showing as below:
During the past 13 years, the highest Dividend Payout Ratio of Bionime was 21.01. The lowest was 0.21. And the median was 1.29.
TPE:4737's Dividend Payout Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.42 * Ranked among companies with meaningful Dividend Payout Ratio only.
During the past 12 months, Bionime's average Dividends Per Share Growth Rate was -100.00% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Bionime was 63.90% per year. The lowest was -35.70% per year. And the median was -4.80% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Bionime (TPE:4737) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Bionime Dividend Payout Ratio Related Terms
Bionime Dividend Payout Ratio Historical Data
* Premium members only.
The historical data trend for Bionime's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4737 vs ISRG, BDX, MDLN: Dividend Payout Ratio Comparison
For the Medical Instruments & Supplies subindustry, Bionime's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionime Dividend Payout Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionime's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Bionime's Dividend Payout Ratio falls into.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Bionime's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionime (TPE:4737) has a Dividend Payout Ratio of 0.00 as of Dec. 2025. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Bionime and its competitors. Over the past decade, Bionime's Dividend Payout Ratio has ranged from 0.21 to 21.01. According to the industry distribution chart, Bionime ranks #999999 out of 281 companies in the Medical Devices & Instruments industry.
Is Bionime's Dividend Payout Ratio too high?
Bionime's current Dividend Payout Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 21.01. Based on the distribution chart, Bionime ranks #999999 out of 281 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bionime has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bionime's Dividend Payout Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bionime ranks #999999 out of 281 companies for Dividend Payout Ratio. This places Bionime in the lower half of its industry. The industry median Dividend Payout Ratio is 0.42. Historically, Bionime's own Dividend Payout Ratio has ranged from 0.21 to 21.01 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Medical Devices & Instruments company?
The median Dividend Payout Ratio among Medical Devices & Instruments companies is 0.42, based on 281 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Bionime and its competitors. For the Medical Devices & Instruments industry, the median Dividend Payout Ratio is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionime's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionime stock overvalued right now?
Based on GuruFocus' analysis, Bionime (TPE:4737) is currently considered Fairly Valued. The stock's GF Value™ is NT$58.88, compared to a current price of NT$56.70 — trading 3.7% below its estimated fair value. The current Dividend Payout Ratio is 0.00. Bionime's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Bionime (TPE:4737), the current Dividend Payout Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bionime (TPE:4737) Overvalued in 2026?
Based on GuruFocus' analysis, Bionime stock appears to be undervalued.
The current stock price of NT$56.70 is trading 3.7% below its estimated GF Value™ of NT$58.88.
GuruFocus considers Bionime to be Fairly Valued.
Key valuation signals for TPE:4737:
Dividend Payout Ratio: 0.00
GF Value™: NT$58.88 vs. price of NT$56.70 (3.7% below fair value)
No single metric tells the full story. See the TPE:4737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bionime Corp is engaged in the manufacturing and selling of medical instruments, providing biotechnology services, examining pharmaceuticals, and selling precision instruments. The company's revenue is derived from the sale of blood glucose meters and test strips to domestic and foreign clients. Geographically, it operates in Algeria, China, Switzerland, the United States, Belarus, Egypt, the United Arab Emirates, and other countries, of which it derives the maximum revenue from Algeria.
65GF Score
Get the complete analysis for TPE:4737
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4737 has been successfully added to your 
